insights_auto
Why is DMYD-B up 2,19%?
Dive Deeperchevron_right
DMYD-B:STO
Diamyd Medical AB
SEK 0,98
arrow_upward
+2,19%(+0,021) 1D
9 ຕ.ລ., 17 ໂມງ 29 ນາທີ 56 ວິນາທີ GMT+2 · SEK
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMYD-B...
Open
SEK 0,95
High
SEK 0,99
Low
SEK 0,92
Mkt. cap
148,45 ລ້ານ
Avg. vol.
759,33 ພັນ
Volume
894,92 ພັນ
52-wk high
SEK 17,88
52-wk low
SEK 0,90
EPS
SEK-1,98
Shares outstanding
134,00 ລ້ານ
No. of employees
44
Open
SEK 0,95
High
SEK 0,99
Low
SEK 0,92
Mkt. cap
148,45 ລ້ານ
Avg. vol.
759,33 ພັນ
Volume
894,92 ພັນ
52-wk high
SEK 17,88
52-wk low
SEK 0,90
EPS
SEK-1,98
Shares outstanding
134,00 ລ້ານ
No. of employees
44
News stories
From web sources and news partners
Simply Wall Street
·
46 ນາທີກ່ອນ
Will Toro (NASDAQ:TORO) Spend Its Cash Wisely?
MarketBeat
·
59 ນາທີກ່ອນ
FIGX Capital Acquisition Corp. (NASDAQ:FIGX) Stock Short Interest Report for September
Yahoo Finance
·
22 ຊົ່ວໂມງກ່ອນ
Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up
Nasdaq
·
1 ມື້ກ່ອນ
WISeSat.Space Holdings Corp. Rings the Opening Bell
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB